Which would benefit the makers of those newer, more expensive drugs. Hmmm.
Interesting....however, there are not inexpensive cancer drugs:o(
Lower priced drugs have lower margins, hence lower incentive to invest / modernize production to meet the increasing FDA regulations. Many drug co’s are making decisions to discontinue manufacturing based on the profitability. some avoid / defer investments until reality sets in.
can you show cases where a more expensive drug is benefiting from the short supply of a generic?